CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2018 Earnings Presentation
17 slides from CelLBxHealth's earnings presentation, Jan 31, 2018
Slide 1: Parsortix Liquid Biopsy Interim Results for the six months ended 31 October 2017
Parsortix Liquid Biopsy Interim Results for the six months ended 31 October 2017 Andrew Newland and Ian Griffiths 31 January 2018 © ANGLE plc 2018 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Highlights
Highlights Liquid Biopsy ANGLE’s Parsortix and Ziplex Positive clinical evidence from successful 400 patient Ovarian systems Cancer studies in Europe and US Simple blood test for personalised cancer care Acquisition of versatile Ziplex® downstream analysis system enables Proven performance with “sam
Slide 4: Financial Highlights for the six months ended 31 October 2017
Financial Highlights for the six months ended 31 October 2017 Six months ended 31 October 2017 2016 Statement of Comprehensive Income £’000 £’000 Comments Revenue 188 219 Research use sales established Cost of sales (54) (43) >145 Parsortix instruments in active use >39,000 blood separations have al
Slide 5: Parsortix system – the complete picture
ParsortixTM system – the complete picture Intact CTCs not just ctDNA compatible with existing downstream analysis techniques ParsortixTM system captures living cancer cells these cannot be present unless the patient has cancer Evidence-based, driven by KOLs and clinical studies Patented product solu
Slide 6: Ziplex high performance multiplex downstream analysis solution
Ziplex® high performance multiplex downstream analysis solution Ziplex® System − benchtop laboratory platform designed for routine and focused multiplex analysis of protein, DNA or RNA biomarkers − sample to answer solution for distributed testing under development HyCEAD chemistry − enables simulta
Slide 7: Benefits of Parsortix CTCs
Benefits of ParsortixTM CTCs 1. CTCs are live cancer cells circulating in the blood known as circulating tumour cells 3. Tissue obtained from simple peripheral blood test 2. cfDNA also known as ctDNA is cell-free circulating fragments of DNA from dead 4. Access to CTCs technically challenging given
Slide 8: Far-reaching market potential
Far-reaching market potential Evidence-based approach to prove performance with ovarian cancer, FDA breast cancer Substantiating value as sample collection platform Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Partnering strategy for widespread deployment © ANGLE plc 201
Slide 9: Clinical applications
Clinical applications 1a 1b 2 3 Research Pilot Verification Validation Discovery Study Study Study Ovarian Cancer Triage Clinical Applications Metastatic Breast Cancer Platform Clearance Prostate Cancer Colorectal Cancer Head & Neck Cancer Lung Cancer Pancreatic Cancer © ANGLE plc 2018 Page 9
Slide 10: Clinical application: ovarian cancer
Clinical application Ovarian studies completed: 400 patients £300 million p.a. market potential 400 patient European (ANG-001) and United Ziplex worked very well with 65 genes in this study States (ANG-003) studies − Medical University of Vienna, Charité and Vivantes Optimisation in progress to impr
Slide 11: Regulatory clearance for clinical use
Regulatory clearance for clinical use Breast cancer FDA clearance progress (400 patient study) Potential to be first FDA cleared system for ANG-002 clinical study commencing shortly harvesting cancer cells from blood − designed to meet FDA regulatory requirements − 200 metastatic breast cancer patie
Slide 12: Non-invasive metastatic breast cancer biopsy
Clinical application under consideration Non-invasive metastatic breast cancer biopsy £1 billion p.a. market potential CTCs harvested and RNA-Seq analysis successful for 100% of patients (21 patient study) CTCs from Parsortix liquid biopsy had similar patterns of expression for 192 genes to the trad
Slide 13: Non-invasive prostate biopsy
Clinical application under consideration Non-invasive prostate biopsy £3 billion p.a. market potential Barts Cancer Institute pilot studies − harvested CTCs in 100% of patients (52 patient study) − number of mesenchymal CTCs showed good correlation to Gleason score (80 patient study) Simple blood te
Slide 14: Co-marketing agreement with leading molecular testing company, QIAGEN
Co-marketing agreement with leading molecular testing company, QIAGEN QIAGEN leading molecular testing company − 500,000 customers and $1.3bn revenues − NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities Selected Parsortix
Slide 15: Growing body of published evidence: recent breakthrough results
Growing body of published evidence: recent breakthrough results 10 publications (30 April 2017: 4) and 19 posters (30 April 2017: 13) Barts Cancer Institute megakaryocytes: Parsortix CMS identifies patients 10x more likely to die University of Maryland micro-tentacles allows testing of drugs on livi
Slide 16: Parsortix patented system developing a world-leading position
ParsortixTM patented system developing a world-leading position in emerging $ multi-billion liquid biopsy market Providing the Complete Picture (viable, intact CTCs for DNA, RNA, and protein analysis not just ctDNA) − Widespread adoption by leading cancer centres in Europe and the United States IRB
Slide 17: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc ANGLE Biosciences Inc 10 Nugent Road 3711 Market Street 50 Ronson Drive, Suite 105 The Surrey Research Park University Science Center 8th floor Toronto Guildford GU2 7AF Philadelphia PA 19104 Ontario M9W 1B3 United Kingdom USA Canada www.ANGLEplc.co